BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsCompany update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s

Open original release

Related news

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

NTLAIntellia2026-07-06 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-07-01 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-03-31 20:05 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-06-05 12:01 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

NTLAIntellia2026-06-01 11:30 EST

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

View all latest news

Sarepta Therapeutics

Sarepta Therapeutics is a biotechnology company focused on rare neuromuscular diseases, especially Duchenne muscular dystrophy. The company’s identity is closely linked to gene therapy, exon-skipping science, and the progress of its rare-disease franchise.

Recent company news

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-04-22 12:30 EST

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-03-31 20:05 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
15.89 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States